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Background: Comorbid anxiety is common in bipolar disorder (BD) and associated with worse clinical 
outcomes including increased suicidality. Despite effective psychological treatments for anxiety, 
research into treating anxiety in BD is underdeveloped. This paper describes a novel psychological 
intervention to address Anxiety in context of Bipolar Disorder (AIBD).  
Methods: Adults with BD and clinically significant anxiety symptoms were randomised to AIBD plus 
treatment as usual (TAU) or TAU alone. AIBD offered 10 sessions of psychological therapy using a 
formulation-based approach. Feasibility and acceptability was evaluated through recruitment, 
retention, therapy attendance, alliance, fidelity and qualitative feedback. Clinical outcomes were 
assessed at baseline, 16, 48 and 80 weeks: interim assessments of relapse at 32, 64 weeks.  
Results: Seventy-two participants were recruited with 88% retention to 16 and 74% to 80 weeks 
(similar between arms).   Therapy participants attended ?̅? 7.7 (SD 2.8) sessions. Therapeutic alliance 
and therapy fidelity were acceptable. Qualitative interviews indicated participants valued integrated 
support for anxiety with BD, and coping strategies. Some suggested a longer intervention period. 
Clinical outcomes were not significantly different between arms up to 80 weeks follow-up.  
Conclusions: AIBD is feasible and acceptable but lack of impact on clinical outcomes indicates 
adaptations are required. These are discussed in relation to qualitative feedback and recent 
literature published since the trial completed. 
1.INTRODUCTION 
Comorbid anxiety is common in BD (12-month prevalence 32- 53%; McIntyre et al. 2006, Otto et al. 
2006): lifetime 60- 90%; Merikangas et al. 2007, Sala et al. 2012) and linked to worse clinical 
outcomes, including higher relapse, worse medication side- effects, poorer psychosocial function 
and higher suicidality (Otto, Simon et al. 2006, Simon et al. 2007, Goes et al. 2012, Goldeberg and 
Fawcett 2012, Sala, Goldstein et al. 2012).  
Despite the importance of anxiety in BD, development of effective psychological treatment is 
limited. Two systematic reviews concluded there is preliminary evidence for structured psychological 
interventions but still a pressing need for specific treatment protocols for anxiety in BD (Provencher 
et al. 2011, Stratford et al. 2015).  A promising initiative in this area has been an investigation of 
feasibility and acceptability of the Unified Protocol for Emotional Disorder (UP: Barlow, Ellard, et al., 
2010; Barlow, Todd et al., 2017) for individuals with BD and at least one comorbid anxiety disorder 
(Ellard, Bernstein et al., 2017). Although UP was not specifically developed with individuals with BD, 
it was argued that its focus on emotional dysregulation was likely to make it appropriate for this 
group. Ellard and colleagues randomised 29 individuals to receive either UP+TAU or TAU alone, with 
approximately 62% retention to end of treatment follow-up (6 months) and similar treatment 
satisfaction in both groups. Greater change over time was reported UP+TAU for clinician-reported 
anxiety and both self- and clinician-reported depression.  
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A key question in developing treatment approaches to anxiety comorbidity is whether to target 
anxiety diagnoses or symptoms. The latter was chosen here for 3 reasons: i) anxiety disorders tend 
to be highly comorbid, especially in BD (Provencher, Hawke et al. 2011) and  multiple separate 
interventions for specific anxiety disorders would be inefficient.  ii) Anxiety-related distress in BD 
often doesn’t fit neatly within an anxiety diagnostic category (Provencher, Hawke et al. 2011, 
Hampshire 2014). iii) Anxiety disorders typically share key elements, including interference with 
functioning and subjective feelings of anxiety, worry and tension (Barlow et al. 2010). 
The aim of this study was to test the feasibility and acceptability of the Anxiety in Bipolar Disorder 
(AIBD) intervention using an RCT design.   
2. METHODS  
This study was preregistered (ISRCTN: 84288072), reviewed and approved by UK NHS Ethics (REC ref: 
10/H1015/83) with a  published research protocol (Jones et al. 2013). 
2.1 Trial design 
A rater-blind individually randomised controlled trial comparing <=10 sessions of integrated CBT for 
anxiety in BD (AIBD), plus treatment as usual (TAU), compared with TAU alone: conducted across 
seven NHS trusts in the North West of England. A nested qualitative study explored feasibility and 
acceptability.   
Participants were randomised by an independent clinical trials unit (MAHSC CTU 9) with randomly- 
sized permuted blocks minimised on gender, number of previous mood episodes (depression and 
mania: <7, 8-19 or >20) and current anxiety (HAM-A score: 0-17, 18-24 or >25). 
To ensure blindness, researchers were housed separately from therapists and had no involvement in 
randomisation or post-randomisation data. Trial participants were instructed to avoid disclosing 
treatment arm. Unblindings were recorded and an alternate blind RA allocated. 
2.2 Recruitment  
Participants were recruited (June 2011-May 2012) from NHS mental health and primary care services 
and voluntary groups. Advertisements in local media, and at NHS and non-NHS sites aimed to 
maximise participant access. All participants provided written informed consent. 
2.3 Inclusion/exclusion criteria  
Inclusion criteria: i) DSM-IV (SCID) verified BD diagnosis (First et al. 1997); ii) Current significant 
anxiety (HADS-A >= 8; Zigmond and Snaith 1983)); iii) Ability to provide informed consent; iv) > = 18 
years.  
Exclusion criteria: i) Current mood mixed episode (or last four weeks); ii) Current suicidal ideation 
with intent.  
2.4 Intervention 
AIBD  development was informed by thematic analysis of individual qualitative interviews (n=21)  
and 3 focus groups (n=21) with individuals with experience of BD and anxiety. These both focussed 
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on what type of support people wanted in relation to their experiences of anxiety. Key themes and 
topics with illustrative quotes are presented in Table 1.  In line with the results of these interviews 
and focus groups, AIBD was developed to be sensitive to the potential impact of anxiety and to offer 
information and structured psychological support to address collaboratively agreed personalised 
therapy goals.   AIBD was offered flexibly in terms of location (client’s home or clinical setting 
according to client preference) and session duration, with sessions supported by client workbooks 
including client therapy record and anxiety recovery plans, lived experience accounts of anxiety and 
BD and information about additional resources and support. Specific CBT strategies were drawn 
from best practice guidance from NICE in relation anxiety and BD available during the period of AIBD 
development (2010-2011 NICE 2004, 2005a,b, 2006).  
Important AIBD elements include flexible engagement, reviewing of positive experiences and coping 
as well as difficulties, and a flexible formulation-driven approach to individual therapy plan 
development. The individualised formulation-driven approach took into account level of 
engagement and motivation and explored links between anxiety and bipolar experiences, including 
issues around functioning, to elicit personally valued treatment goals.  On the basis of this 
information, consideration was given to the client’s key anxiety concerns and which of these to 
target as goals within therapy. The specific intervention plan in each case was guided by the 
individual formulation, and incorporated appropriate cognitive behavioural strategies focussed on 
addressing anxiety experiences and consequent behaviour. This included CBT to facilitate adaptive 
approaches to dealing with anxiety and where appropriate addressing the impact of depressed or 
elevated mood on these issues as well. Typically the CBT approach included learning more about the 
nature of their anxiety symptoms and developing coping strategies for dealing with them using CBT 
techniques including graded exposure/interoceptive exposure, relaxation and breathing techniques, 
cognitive restructuring, behavioural experiments, thought monitoring/challenge and adaptive 
problem solving.  Where it was clear that mood instability and relapse were strongly associated with 
anxiety difficulties, mood-monitoring techniques, detection of early warning signs for problematic 
mood changes and coping strategies in relation to these early warning signs regularisation of routine 
and mood related problem-solving strategies were also a feature of therapy.   The information from 
all phases was finally drawn into an anxiety recovery plan highlighting key challenges for the client 
and which techniques they have selected to be useful in addressing them (including strategies 
already successfully used by the client and new strategies developed in therapy). The relative 
emphasis between anxiety and mood strategies varied between clients based on their individual 
goals and formulation. Table 2 provides a brief summary of therapy progress for two illustrative 
clients.  This approach differs from UP in being specifically developed for, and with, individuals with 
bipolar disorder, with a strong focus on individual formulation, a flexible personalised approach to 
relative emphasis of the intervention stages, incorporation of mood relapse prevention approaches 
if required and omission of mindfulness as an intervention strategy (as this is not currently 
recommended by NICE in relation anxiety or depression). 
 (Table 2 AIBD phases; relative emphasis depended on individual goals and formulation).  
2.5 Therapists 
AIBD was delivered by three therapists; all met BABCP accreditation criteria, trained in AIBD and 
received weekly clinical supervision from SJ.  
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2.6 Primary Feasibility and Acceptability Outcomes  
Feasibility and acceptability of AIBD were evaluated in terms of levels of recruitment into the trial, 
retention of participants in both arms of the study, treatment fidelity, assessed by the Cognitive 
Therapy Scale-Revised version (CTS-R; Blackburn et al. 2001) and the AIBD Fidelity Scale (available 
from authors on request), therapeutic alliance (Work Alliance Inventory, WAI-S ; Tracey and 
Kokotovic 1989) and therapy attendance and client evaluation.   
2.7 Qualitative interviews 
A nested qualitative study was conducted with 17 therapy participants (purposively sampled on age 
and gender, HADS-A score at recruitment, number of sessions attended, previous relapse history) to 
explore subjective experiences of AIBD.   
2.8 Clinical Outcomes  
Face-to-face assessments were conducted at initial interview (to confirm diagnosis), baseline, 16, 48 
and 80 weeks: interim telephone assessments 32 and 64 weeks. Observer-ratings were obtained at 
each assessment. Self-report measures not obtained at interim assessments. 
Primary clinical outcome was impact of AIBD on observer- and self-reported anxiety (Hamilton 
Anxiety Rating Scale, HAM-A; Hamilton 1959, Shear et al. 2001: State-Trait Anxiety Inventory, STAI; 
Spielberger 1983), time to relapse and symptoms of mania and depression (SCID for DSM-IV 
Longitudinal Interval Follow-up Evaluation, SCID LIFE; Keller et al. 1987, First, Spitzer et al. 1997); 
Hamilton Depression Rating Scale (Hamilton 1960) and Bech-Rafaelsen Mania Scale, MAS (Bech et al. 
1978).  
Additional clinical outcomes were personal recovery (Bipolar Recovery Questionnaire, BRQ; Jones et 
al. 2013); Quality of Life (Quality of Life in Bipolar Disorder Scale, QoL.BD; Michalak et al. 2010), and 
functioning (Personal and Social Performance Scale, PSP; Morosini et al. 2000).  
2.9 Data analysis  
Primary outcome information on recruitment and retention levels, therapy fidelity, alliance, 
acceptability and completion were all summarised with descriptive statistics. Sample characteristics 
including baseline mood and anxiety were reported. 
  
The clinical and functional outcome measures were analysed using the methods that would be 
employed in a full trial. The intention-to-treat principle was employed throughout. For the time to 
relapse survival analyses, covariates were treatment arm, gender, number of previous bipolar 
episodes (8-20 and more than 20, both versus 1-7) and baseline HAM-A total in a cox regression 
model. 
  
A two level linear mixed model was fitted with time as a discrete covariate and an unstructured 
covariance matrix at level 2 using the mixed procedure in Stata (2015). This model corresponds to a 
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repeat measure model but allows for missing data at some time points, enabling subjects with 
incomplete data to be included in the analysis. The normality assumption of these models was 
checked using a normal probability plot of model residuals. A model with a discrete time by 
treatment interaction was fitted to estimate the treatment effect and the 95% confidence interval at 
each follow-up time point (Model 1). If there was no interaction at the 5% level based on a Wald 
test, the interaction term was omitted and the overall treatment effect was estimated from this 
simpler model (Model 2). The same covariates described above were used for these models, 
additionally adjusting for baseline value of the outcome. A baseline response by discrete time 
interaction term was also included.  
Qualitative interviews were audio-recorded, transcribed verbatim and thematically analysed to 
explore participants’ experiences of AIBD (Braun and Clarke 2006). Themes were compared against 
the data using a constant comparative approach by a multidisciplinary panel (CH, SP, LR, SJ, RL). 
Interviews were conducted until thematic saturation was achieved.  
 
3 RESULTS  
3.1 Participants 
Participants were mainly white British females with a chronic course of BD, (>70% had over 20 mood 
episodes at baseline, Table 3) aged over 40 years (AIBD ?̅?= 45.5, SD = 10.7; TAU ?̅?= 42.9, SD = 16.6).  
The majority had a Bipolar I diagnosis (n = 62, 86%), were either divorced or never married (n = 48, 
67%) and parents (n = 42, 58%). Although most participants had at least commenced further 
education (n = 55, 76%), only a minority were in employment (n = 28, 39%). Of those not in work, the 
majority were in receipt of sickness/disability benefits (n = 23 of 44, 52%). Comparing AIBD with TAU   
the only substantial differences were in relationship status (twice as many married or cohabiting in 
AIBD), employment (approximately 10% more AIBD participants in work) and referral source (two-
thirds of referrals in AIBD were self-referrals compared with one third of TAU).  
At baseline, consistent with HADS-A screening, 85% of participants met criteria for at least one 
current anxiety disorder; Generalised Anxiety Disorder (GAD) and social phobia were the most 
common (Table 2). More AIBD participants met criteria for two or more anxiety disorders (59% vs. 
40%).Rates of Social Phobia, Agoraphobia, Post-Traumatic Stress Disorder(PTSD), Panic ± 
Agoraphobia, and Specific Phobia were all numerically higher in AIBD versus TAU.  
 STAI-S and STAI-T scores at baseline (Table 6) were elevated compared with general populations 
and anxiety group norms1 (Spielberger 1983): HAM-A scores were in the normal range.   
Observer-rated measures scores (indicated very mild depression HAM-D(Hamilton 1960)) 
(Zimmerman et al. 2013) and extremely low mania scores (MAS) (Bech 2012) at baseline, both arms. 
                                                          
1 General population (means; STAI-S, 35.88-36.03; SD, 10.52-11.07: STAI-T  35.03-35.06; SD, 8.88-9.31) and 
diagnosed anxiety group (without BD) (STAI-S: M = 49.023, SD = 11.62: STAI-T M = 48.08, SD = 10.65) 




Personal recovery scores were higher at baseline than in a previous RCT for BD (Jones et al. 2015). 
Quality of life (QoL-BD) is similar to that reported in the measure development paper (Michalak, 
Murray et al. 2010), personal and social functioning (PSP) indicates no more than mild impairment in 
functioning (Morosini, Magliano et al. 2000).  
3.2 Primary Outcomes 
3.2.1 Feasibility and acceptability  
Figure 1 presents recruitment and retention rates according to CONSORT criteria (Schulz et al. 2010). 
Of 122 people screened, 14 declined, 9 were uncontactable and 27 did not meet study inclusion 
criteria. Of 72 randomised participants, 32 (44%) were recruited by clinician referral.  Twenty-five 
AIBD participants came via self-referral (62.5%), compared to 15 (37.5%) TAU (see Table 3).  
Recruitment target was met (n = 72; 59% of those screened for eligibility).  Retention was 88% (n = 
63) to end of therapy (16 weeks), 78% (n = 56) to 32-week follow-up, 75% (n = 54) to 48- and 64-
week follow-up, and 74% (n = 53) to 80-week follow-up (feasibility target 75% ± 10% to 80 weeks 
(Jones, McGrath et al. 2013).  Retention rates at least as high in TAU as in AIBD (Figure 1). Measure 
completion rates for retained participants varied from 97% at baseline to 79% at 80 weeks (Table 4).   
Single unblindings were reported in seven AIBD and four TAU participants: an alternate blinded-RA 
was allocated in each case. Two participants lost to follow-up died during the final follow-up period 
for reasons unrelated to the trial.   
Mean AIBD attendance was 7.7 (SD = 2.8); two participants attended zero session, 84% (n = 31) 
attended >=4 sessions and 59% (n = 22) attended 9-10 sessions.  
Adherence to the therapy protocol and CTS-R were independently assessed for 26 randomly 
selected therapy recordings across early (sessions 1-2), mid (sessions 4-5) and late (sessions 7-10) 
phases. Adherence to the treatment protocol was 77.65% (SD 10.33) across the above phases. CTS-R 
mean was 47.1 (SD = 5.03); above threshold criteria for CBT competence of 36 (Keen and Freeston 
2008) and consistent across sessions; early, ?̅? =47.5,SD = 5.74, mid, ?̅? =47.4 SD = 5.24,late, ?̅? =46.1 
SD = 3.76).   
Therapeutic alliance was assessed after sessions 3 and 10 with complete data from 23 clients at 
session 3 (?̅? =71.22, SD 9.20) and 16 at session 10 (?̅?= 72.88, SD 9.62): therapist ratings were 
obtained for 23 clients at session 3 (Mean 65.78, SD 7.52) and 15 at session 10 (?̅? = 70.89, SD 6.45). 
Ratings at both stages were higher than reported in previous psychological intervention studies of 
complex psychological problems including BD (Davidson et al. 2006, Jones, Smith et al. 2015) 
3.2.1.1. Client ratings of therapy 
AIBD clients rated therapy on two 0–10 scales. Firstly, how helpful they thought the therapy was 0 
(not at all) to 10 (extremely); secondly, whether they would recommend it to someone with similar 
problems 0 (definitely not) to 10 (definitely yes). Data was available for 21 participants: experience 





3.2.1.2 Qualitative interview findings (see Table 5 for illustrative quotes) 
Participants indicated they valued the intervention in contrast with previous forms of support 
received. They identified benefits of treating anxiety and BD together in contrast with previous 
experiences of having these problems addressed separately. AIBD is relatively brief; several 
participants found this helpful in providing a clear structure and personally-identified targets. 
However, others wished therapy had been longer, although without specifying omissions from 
therapy as delivered. Coping strategies learnt in AIBD were helpful in: i) overcoming anxiety-based 
social isolation and functional limitations; and ii) increasing confidence in dealing with BD.  
3.3 Secondary self- and observer-reported outcome measures 
Key clinical outcomes were anxiety symptoms, sub-syndromal mood symptoms, (see Table 6-7) and 
time to relapse (Figures 2-4).  The treatment by time interaction was significant for STAI-State but 
not STAI-Trait, with the lower scores at weeks 16 and 48, in AIBD vs TAU, although not by week 80.  
Observer-rated anxiety (HAM-A), depression (HAM-D) and mania (MAS) remained low throughout in 
both arms; significant treatment by time effects for MAS only with higher score at 48 weeks and 
lower at 80 weeks for AIBD.   
37% (n=13) of TAU and 43% (n=16) of AIBD had a relapse of either mania or depression by 48-week 
follow-up, and 49% (n =17) of TAU and 59% (n=22) of AIBD by 80 weeks. Neither these nor 
differences for mania or depression alone were significant.  
There were trends toward significant interactions between time and treatment group for personal 
recovery (BRQ) and personal and social performance (PSP) but not quality of life (QoL.BD): patterns 
suggested improvements in in AIBD at 16 weeks versus TAU for BRQ and to 48 weeks for QoL.BD.  
Effect sizes for all comparisons are small-medium. 
 
4 DISCUSSION 
This paper reports the first RCT feasibility study of a novel psychological intervention for anxiety in 
BD. The approach is feasible: 59% of screened participants were randomised to feasibility trial which 
compares well with previous CBT for BD trials (Lam et al. 2005, Scott et al. 2006, Jones, Smith et al. 
2015).  Retention rate to 80 weeks was 72%, within the target of 75% ± 10% and comparable to 
other CBT trials in BD: 67% follow-up to 15 months (Jones, Smith et al. 2015); 75% to 18 months 
follow-up(Scott, Paykel et al. 2006) . Furthermore, retention was broadly balanced across arms, 
indicating absence of resentful demoralisation (Brewin and Bradley 1989).  No trial-related adverse 
events were reported.  The arms did differ in referral route with more participants in the therapy 
being recruited through self-referral. However both arms were similar in terms of demographic 
characteristics except for the larger proportion of the therapy arm who had >=2 anxiety disorders. 
Participants were over 40 years old, and over two-thirds had at least 20 prior episodes; more than 
those reported in some specific relapse prevention trials (Lam, Hayward et al. 2005, Meyer and 
Hautzinger 2012).  Only a third of the participants were in work, with most others in receipt of 
sickness/disability benefits.   
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85% of participants met criteria for anxiety disorders. Mood symptoms were low throughout and 
participants were relatively high functioning on personal recovery, quality of life and personal and 
social functioning measures. Participants attended 77% of AIBD sessions offered, indicating a 
significant commitment to AIBD.  Several previous BD therapy trials didn’t specify attendance rates 
(Lam et al. 2003, Scott, Paykel et al. 2006).  Meyer reported 14.5% of therapy participants attended 
< 80% of sessions, the majority whom attended < 50% (Meyer and Hautzinger 2012). More specific 
data indicated individual recovery therapy attendance of 78% of sessions (Jones, Smith et al. 2015). 
Thus, AIBD attendance rates are comparable with the published literature. Acceptable therapeutic 
alliance and therapy fidelity were achieved. Client ratings of therapy usefulness and likelihood of 
recommending therapy were high (average >9/10 in both cases) but available for only 21 of 37 AIBD 
participants and so not definitive. In-depth qualitative interviews indicated the participants valued 
AIBD, linked to improvements in both symptoms and functioning in a number of clients. Some 
participants wanted a longer intervention, although others were happy with it as delivered.  
The trial was not powered to test impact of AIBD on clinical outcomes and effect size estimates were 
imprecise and largely non-significant. Self-reported anxiety (STAI-S) indicated potential 
improvements in anxiety to 48, but not 80 weeks post-baseline. In contrast, observer-rated anxiety 
(HAM-A) was low throughout the trial. This discrepancy is potentially important for further trial 
development. Based on the screening data, the reports of therapy clients and the self-report 
measurements, it seems possible HAM-A underestimated perceived anxiety. 
Observer measures indicated low depression (HAM-D) and mania (MAS) consistent with recruitment 
of euthymic participants and remained throughout follow-up.  
Personal recovery (BRQ) but not personal and social functioning (PSP) improved more rapidly for 
participants in AIBD during therapy, whilst Qol.BD was numerically improved to 48 weeks but gains 
were not sustained at later follow-up.  
Mood relapse rate was lower than that reported by Meyer (64.5% at 80 weeks; (Meyer and 
Hautzinger 2012) and Lam (75% at 30 months; Lam, Hayward et al. 2005) and comparable to Scott et 
al (52% at 18 months; Scott, Paykel et al. 2006). Although numerically higher in AIBD arm, the hazard 
ratio did not approach statistical significance.   
Overall the current findings support the feasibility and acceptability of the trial design and the AIBD 
intervention. However it is important to acknowledge the lack of signal overall for the trial based on 
current findings.  This suggests building on evidence for the importance of the integrated approach 
to anxiety in BD with an intervention revised to address potential factors impacting on efficacy, as 
indicated by qualitative feedback and by the wider literature emerging since completion of the trial.  
The most obvious trial for comparison with the present study is that of Ellard and colleagues, given 
their specific focus on addressing anxiety in BD through the use of UP (Ellard, Bernstein et al., 2017).  
There are several factors that may account for the difference in outcome findings. Although both 
have more female and predominantly white participants, it is not possible to compare clinical 
severity with respect to prior mood episodes or current anxiety disorders as these were not reported 
by Ellard. The present study had broader inclusion criteria and therefore did not exclude potential 
participants on evidence of psychotic symptoms, substance use issues or suicidal ideation without 
intent, in contrast to Ellard. It is therefore possible that in our study participants had more severe 
and complex clinical issues. Our analytic approach used time as a discrete variable in contrast to 
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Ellard for which it was a continuous variable.  The  advantage of the discrete time approach is that it 
provides estimates of the treatment effect at each assessment point adjusted for baseline covariates 
and is superior to separate analysis of covariance at each time-point, as information is shared across 
time-points supporting a missing at random assumption. Finally, it is unclear from their description 
whether the baseline assessment is included as a predictor or a response in their model.  
Our findings can also be usefully interpreted in light of outcomes from the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD) STEP-BD study which explored the impact of 
lifetime anxiety disorder comorbidity on outcome from structured psychological therapy. In 
particular whether this moderated the relationship with clinical recovery in response to structured 
psychotherapy (cognitive behaviour therapy, family focussed therapy or interpersonal and social 
rhythm therapy) compared to a three session control condition of collaborative care for depressed 
BD participants  (Deckersbach, Peters et al. 2014). Participants with one lifetime anxiety disorder 
showed greater improvement in response to structured therapy compared to collaborative care. 
This difference was not apparent for those with no lifetime history or with more than one lifetime 
anxiety diagnosis. This moderation affect appeared to be linked with the much poorer response of 
those with lifetime anxiety to the collaborative care intervention compared to those with no lifetime 
history (49% vs 62% recovery ) rather than a differential response to structured psychotherapy (66% 
vs 64% recovery). This report did not indicate anything about responses patterns in relation to 
anxiety symptomatology or functional outcomes. These findings with respect to participants with BD 
and current depression require further prospective exploration including study of wider samples 
including those outside current mood episodes.  A review of the effectiveness in general of 
psychological therapy for anxiety in bipolar spectrum disorders concluded that CBT including anxiety 
components may improve anxiety symptoms in cyclothymia among other bipolar spectrum 
conditions but that development of both psychological models and treatment protocols specific to 
anxiety in bipolar disorder are a priority (Stratford, Cooper et al., 2015).  
There is accumulating evidence that individuals with BD typically respond to psychological therapy 
better when delivered earlier in the course of their disorder. This has been reported in relation to 
CBT and group psychoeducation and is consistent with recent positive outcomes for a trial of 
recovery focused therapy for recent onset BD (Jones, Smith et al. 2015; Scott, Paykel et al., 2006) It is 
therefore possible that focussing the intervention in the future more clearly on individuals with 
more recent BD onset might lead  to stronger clinical effects. Although we considered post-hoc 
additional exploratory analysis of the relationships between severity and outcome in the current 
sample, we concluded that this would be inappropriate with relatively small participant group, 
consistent with recent CONSORT guidance (Eldridge, Chan et al, 2016).  
Strengths included comprehensive participant assessment, extensive follow-up post-intervention 
and use of mixed methods to explore participants’ therapy experiences.  
The trial was successful in demonstrating feasibility and acceptability of selection, recruitment and 
intervention procedures. People took therapy when offered, and retention was acceptable.  
Secondary clinical data present a mixed picture, with most promising outcomes in self-reported 
anxiety and quality of life. RCTs of CBT for anxiety typically report follow-up period up to 48 weeks, 
which may be appropriate for a future AIBD trial (Covin et al. 2008). Although AIBD was generally 
well received, some participants wanted more sessions.   Extending AIBD to 12-15 sessions, would be 
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consistent with NICE guidance interventions for anxiety (NICE 2011). More robust clinical outcomes 
might be obtained by opting for more restrictive inclusion criteria particularly with respect to 
duration of BD course. If successful, a definitive trial employing a revised version of the AIBD 
intervention would provide a timely addition to therapeutic options for BD consistent with the 
importance of anxiety in NICE BD guidelines (NICE 2014).  
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Table 1. Summary treatment development information from individual interviews and focus  groups 
Individual interviews  Issues Quotes 
Therapy experiences  Recognition of the impact 
anxiety can have.  
Collaborate to personalise 
individual therapy goals 
“the GP understands nothing 
about anxiety.. . ., tells them 
there’s 
something else wrong with 
them . . .. Or gives them the 
wrong medication 
er . . . doesn’t realise how 
serious the anxiety is so 
doesn’t recommend them to 
a psychiatrist or a 
psychologist.” AA018 
“I felt worried more ….. and 
more … and I felt more unable 
to disclose information, 
because I 
didn’t know if they were on 
my side you know. So I think 
it’s very important to 
establish a bit of trust . . .A054 
‘I just want to know why’: 
Knowledge as power 
Importance of specific 
information about the nature 
of anxiety and relationships to 
mood experiences 
“.. I always think knowledge 
is, knowledge is power. And, 
and the more I know, 
the more better able I am to 
handle a situation which is not 
within my control” AA018 
Limitations of drug treatment Drug treatments for anxiety 
seen as sometimes unhelpful 
and even worsening anxiety. 
Strong support for 
psychological approaches.  
“… medication is needed but 
medication alone doesn’t do 
anything 
for anxiety, and it is just not 
active at all.” AA054 
“they tried me on a, a mixture 
of medication . . . and the first 
one 
actually made me . . . a damn 
sight worse….” AA008 
Cognitive and behavioural 
strategies  
importance of having 
effective approaches to deal 
with anxiety related thoughts 
and behaviour Awareness 
that these approaches are 
difficult to identify or apply 
without structured support 
“When you are dealing with 
emotions like I was dealing 
with, it’s hard enough just to 
cope 
with that, never mind trying 
to analyse yourself, because 
there is not many people can 
do that, it’s the 
hardest analysation there is.” 
AA022 
Focus Groups   
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Content Information and support in 
relation to both BD and 
anxiety 
Recognition of the positive 
emotions associated with 
overcoming challenging 
situations and providing 
support to address these 
Genuine collaboration around 
treatment targets and 
potential outcomes 
Opportunities for family or 
key clinician to attend key 
sessions to support change 
“If a therapist is aware of the 
bipolar running alongside the 
anxiety erm they’ll probably 
get less 
frustrated, and there might be 
tools that they can help . . .” 
P006 
 
“There’d be nothing wrong in 
you saying ‘this is how I want 
this 
to go’. And someone else 
might want it to go a different 
way and they’d be able to 
negotiate it at 
that time rather that it being 
built.” P001  
 
“Yeah. But it has to be my set 
of goals. Not you coming in 
and saying ‘Right I want you 
to be mood 
free . . . in 6 weeks’ time’.” 
P002 
Support materials Flowcharts/work sheets to 
self-monitor progress in 
therapy and as a post therapy 
resource 
Engaging support materials 
including lived experience 
accounts and links to other 
resources/organisations 
“…and the worksheets as well, 
you know, when I was in the 
mood, even though a couple 
of weeks 
later it might not felt like it 
was working again, you can . . 
. keep going back to it”. P004  
“But in a manual you can go 
back in to tap in and tap out 
of, I think it’s a good idea. …. 
So if you can keep going back 
to it ‘cause we don’t always 
get the computer up”. P005  
Barrier and facilitators Importance of timely access 
to therapy 
Support for time limited 
approach deliverable by a 
range of disciplines to 
minimise waiting lists. 
“Yes, getting through the GP 
to get the referrals there is 
not an awful lot of places now 
and waiting 
lists are ridiculously long.” 
P004 
 “We’d want you to be able to 
quantify it at the end of your 
10 weeks or whatever and say 
well this is what you expected 
to get out of it. Did you or 
didn’t you?” P007 
I think it would be really 




delivering the programme, 
which sounds really good, 
you know, if you can get social 
workers and nurses and 
everyone to learn a package 
or whatever” P001  
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Table 2. Phases of Treatment of AIBD 
Phase Focus/Content  ‘Sarah’ ‘James’  
1 Introducing the anxiety 
approach 
Psychoeducation regarding 
thoughts feelings and 
behaviour links relevant to 
anxiety and bipolar disorder 
Psychoeducation regarding thoughts 
feelings and behaviour links relevant 
to anxiety and bipolar disorder 
2 Collecting information 
about current and 
historical anxiety/mood 
and functioning 
10 year history of BD starting at 
University, 3 year history of 
panic attacks  
27 year history of BD starting with 
major depression and overdose 
following relationship break down, 6 
year history GAD and social phobia 
symptoms 
3 Identifying anxiety 
related therapy goals 
Primary goal reduction in panic 
attacks 
Primary goal to improve 
management of anxiety and improve 
social life 






Had isolated herself to avoid 
triggers of mania and became 
more anxious about leaving 
home. Panic triggered on 
seeing an ex-colleague when 
had seen her when ill. Began to 
recur without obvious triggers. 
At first sign of panic symptoms 
would return home and lie 
down.  
Increasingly avoidant of social 
contact and relationships. Although 
feels lonely much of the time he 
found social activities anxiety 
provoking and was concerned this 
will would escalate uncontrollably 
and cause a mood episode. Believed 
mood fluctuations always likely to 
lead to mood episode.  
5 Identifying and applying 
CBT techniques to 
facilitate positive 
coping with anxiety 
Examination of thoughts, 
feelings and behaviours linked 
to leaving feared situations 
provided rationale for graded 
exposure and behavioural 
experiments. 
Trained in relaxation and breathing 
techniques, applied in situ in social 
situations outside the home. Record 
of anticipated vs actual outcomes 
and impact of this on anxiety related 
cognitions and mood  
6 Identification and 
application where 
appropriate of CBT 
techniques enabling 
positive coping with 
mood instability 
Amended early warning signs 
and coping plan to remove 
avoidance items 
Psychoeducation about normal mood 





7 Development and 
completion of  anxiety 
recovery plan 
Progressed through hierarchy 
from being able to view old 
colleagues on facebook to 
visiting her old work place and 
meeting an ex-colleague for a 
cup of tea.  Anxiety recovery 
plan summarised key messages 
from therapy and longer term 
plans for self-management 
Improved understanding of mood 
variation and confidence in managing 
anxiety. This led to increased social 
activities with a plan that includde 
key messages from therapy and 
longer term plans for self-
management  
8 Sharing lessons from 
therapy with key 
stakeholders (clinician 
and/or carer) 
Anxiety recovery plan shared in 
joint session with Sarah and 
her family  
Anxiety recovery plan shared with 
James’s care coordinator  
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Table 3. Baseline sociodemographic and clinical characteristics of clinical sample  
Characteristic AIBD, N = 37 
No. (%) 
TAU, N = 35 
No. (%) 
Gender   
Male 13 (35.1)  10 (28.6)  
Female 24 (64.9) 25 (71.4) 
Ethnicity   
White British 33 (89.2) 32 (91.4) 
Other white 0 1 (2.9) 
Asian other 0 1 (2.9) 
British Asian 2 (5.4) 1 (2.9) 
Not stated 2 (5.4) 0 
Number of previous episodes   
≤7 4  (10.8)  3 (8.6)  
8-19 7 (18.9)  6 (17.1)  
20+ 26 (70.3) 28 (74.3) 
Bipolar Status   
Bipolar I 31 (83.8)  31 (88.6)  
Bipolar II 6 (16.2) 4 (11.4) 
Marital Status   
Married or cohabiting 17 (45.9) 7 (20.0) 
Divorced/annulled/separated 9 (24.3) 13 (37.1) 
Never married 11 (29.7) 15 (42.9) 
Number of children    
0 15 (40.5) 15 (42.9) 
1 7 (18.9) 4 (11.4) 






Education   
Year 7-11 (No GCSE) 3 (8.1) 0 
GCSEs or equivalent 6 (16.2) 8 (22.9) 
Further or higher education not 
completed 
7 (18.9) 4 (11.5) 
Further/ higher or postgraduate 
education completed 
21 (56.7) 23 (65.7) 
Working   
No 21 (56.8) 23 (65.7) 
Yes 16 (43.2) 12 (34.3) 
Source of referral   
NHS 12 (37.5) 20 (62.5) 
Self 25 (62.5) 15 (37.5) 
No. current anxiety disorders    
0 5 (13.5) 6 (17.1) 
1 10 (27.0) 15 (42.9) 
>= 2 22 (59.4)  14 (40.0)  
Current anxiety disorders   
Social Phobia 12 (32.4)  9 (25.7)  
Agoraphobia 6 (16.2)  4 (11.4)  
GAD 19 (51.4)  18 (51.4)  
PTSD 10 (27.0)  7 (20.0)  
Panic +/- Agoraphobia 9 (24.3)  6 (17.1)  
OCD 5 (13.5)  6 (17.1)  
Specific Phobia 9 (24.3) 6 (17.1) 
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Table 4. Completion of measures by trial arm and assessment timepoint 
Treatment arm Baselinea (0 weeks), 
No. (SD) 
16 weeks,  
No. (SD) 
48 weeks,  
No. (SD) 
80 weeks,  
No. (SD) 
AIBD 36 (97.3) 28 (90.3) 20 (74.1) 20 (76.9) 
TAU 34 (97.1) 27 (84.4) 22 (84.6) 22 (84.6) 




Table 5.  Post Therapy qualitative interview findings 




‘And it is the only therapy I have had in all my... I have had anxiety 
since I was what, about 15 and that is the only thing that worked 
for me was that CBT [SIC] therapy.’  (AN003) 
Benefits of treating anxiety 
and BD together  
‘Normally people do them separately and trying to put them 
together when you are ill is just... not easy at all… if you have got 
them separate it's like skirting round each issue, but putting them 
together …….. a person that deal with them all, and will go slowly 
over everything so you know what to expect, it is so much better, 
definitely.’  (AN007) 
Treatment duration   ‘it was 10 sessions, and that were it, but the 10 sessions 
meant that the goals that were laid out at session one, those were 
the goals that were worked at, and those were the goals that 
were achieved by the end and that is a far better way of working.’ 
(AN001)  
‘I remember thinking I didn't want them to come to an 
end. But I couldn't have told you, or couldn't have 
probably pinpointed aspects that I needed more to cover I 
think I was just... gaining so much that I kind of felt maybe 
there was more to gain as well you know if I had carried 
on.’  (AN008)  
 “it's good when you have the sessions but once they 
finish you feel, I felt like lost, and CBT is ok during 
treatment but long term, putting it into practice day to 
day, you know it's difficult to remember instantly all the 
tips, and that.”  (AN006) 
 
Benefits of coping 
strategies  
‘it has been crippling for me over the years. I have had a number 
of breakdowns, and each time it's always been the anxiety that 
has kept me prisoner in my own home, it has stopped me from 
socialising, and progressing so this time, I have healed better and 
with coping strategies that have allowed me to do things, a lot 
quicker than before.’ (AN008) 
‘prior to becoming part of this study I thought my bipolar disorder 




it... and through this study, now I own it and I control it... I... 
through this study and through the work that I did with [research 
assistant] and [therapist] it give me, renewed belief and… made 




Table 6.  Summary of Continuous Clinical Outcome Measures by time in AIBD and TAU groups 
 
Measure  AIBD TAU 
 Week Mean SD n Mean SD n 
STAI-
State 0 
47.1 11.2 36 48.0 15.1 35 
 16 44.3 14.3 30 47.7 11.0 31 
 48 40.8 12.2 23 44.5 14.2 24 
 80 48.7 15.0 24 41.7 15.1 24 
STAI-
Trait 0 
53.7 8.2 37 53.4 11.3 35 
 16 51.5 11.4 30 52.6 9.9 31 
 48 47.9 12.6 23 50.3 10.9 24 
 80 49.6 11.2 24 46.3 13.1 23 
HAM-D 0 8.7 5.1 37 8.0 5.5 35 
 16 10.1 7.8 31 10.5 7.7 31 
 32 9.2 7.5 25 8.9 7.6 27 
 48 8.7 7.9 24 7.9 6.3 25 
 64 9.8 7.0 26 7.4 8.6 23 
 80 9.1 7.0 27 8.7 8.0 26 
HAM-A 0 9.1 6.1 37 9.8 7.8 35 
 16 10.3 9.2 31 11.0 7.7 31 
 32 9.7 8.1 25 10.8 9.9 27 
 48 10.2 9.1 24 10.8 8.8 25 
 64 11.6 8.1 26 11.1 11.4 23 
 80 12.3 9.1 27 11.3 10.6 26 
MAS 0 2.2 2.4 37 2.5 2.9 35 
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 16 2.1 2.5 31 2.2 2.1 31 
 32 1.5 2.9 25 2.6 4.1 27 
 48 3.4 5.0 24 2.0 3.0 25 
 64 2.9 3.3 26 3.7 4.9 23 
 80 2.4 3.7 27 4.8 5.8 26 
BRQ 0 2,107 374 36 2,161 405 34 
 16 2,248 411 31 2,146 401 27 
 48 2,326 374 21 2,351 480 23 
 
80 2,318 379 20 2,398 497 23 
PSP 0 73.16 10.13 37 71.77 12.40 35 
 16 73.68 12.64 31 71.52 12.02 31 
 48 74.91 14.95 23 72.83 15.20 24 
 80 71.12 13.56 25 78.14 16.02 22 
QoL BD 0 142.6 28.4 36 150.5 36.7 34 
 16 147.0 31.8 30 143.7 30.6 31 
 48 157.1 31.2 21 153.1 32.3 23 




Table 7.  Repeated measures analyses of anxiety, mood and functional outcomes  










   
  
M1 16 -2.39 -7.45 2.67 -0.188 0.355 
 
48 -2.50 -8.11 3.11 -0.189 0.382 
 
80 8.49 1.58 15.41 0.564 0.016 
Time by treatment interaction     0.001* 
STAI-Trait 
   
 
 
M1 16 -0.98 -5.16 3.20 -0.092 0.645 
 
48 -1.37 -6.64 3.90 -0.116 0.611 
 
80 3.70 -1.75 9.15 0.304 0.184 
Time by treatment interaction  
   
 0.072* 
M2 No interaction term -0.403 (-4.38, 3.57) -0.035 0.842 
HAM-A 
    
 
 
M1 16 -0.09 -3.33 3.16 -0.012 0.959 
 
32 -0.30 -4.00 3.39 -0.040 0.872 
 
48 0.71 -3.38 4.80 0.100 0.734 
 
64 1.43 -3.06 5.92 0.184 0.533 
 
80 1.88 -2.59 6.35 0.250 0.409 
Time by treatment interaction    0.027 0.798* 
M2 No interaction term 0.246 (-2.44, 2.93)  0.858 
HAM-D 
 
     
M1 16 -0.22 -3.74 3.30 -0.026 0.901 
 
32 1.28 -2.45 5.00 0.141 0.501 
 
48 1.68 -2.17 5.53 0.188 0.393 
 




80 0.91 -2.68 4.49 0.092 0.620 
Time by treatment interaction     0.861* 
M2 No interaction term 0.980 (-1.46, 3.42) 0.131 0.431 
MAS 
 
     
M1 16 0.05 -1.04 1.14 0.022 0.928 
 
32 -0.63 -2.25 1.00 -0.176 0.450 
 
48 1.84 -0.26 3.94 0.449 0.086 
 
64 -0.89 -3.20 1.42 -0.216 0.449 
 
80 -2.14 -4.64 0.36 -0.442 0.094 
Time by treatment interaction     0.032* 
BRQ 
    
 
 
M1 16 138.40 -33.06 309.80 0.341 0.114 
 
48 -22.90 -199.90 154.10 -0.053 0.800 
 
80 -86.80 -269.10 95.80 -0.195 0.352 
Time by treatment interaction 
   
 0.063* 
M2        No interaction term 47.4 (-93.1 187.9) 0.111 0.508 
PSP       
M1 16 1.00 -4.35 6.35 0.089 0.715 
 48 0.27 -7.07 7.60 0.022 0.943 
 80 -8.16 -15.48 -0.83 -0.541 0.029 
Time by treatment interaction     0.072* 
M2        No interaction term 1.22  -5.51 3.05 -0.088 0.574   
QoLBD       
M1 16  4.92 -8.69 18.53 0.158 0.479 
 48 2.81 -12.20 17.81 0.088 0.714 
 80 -4.62 -21.19 11.95 -0.131 0.585 
Time by treatment interaction      0.327* 
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M2        No interaction term 3.55 -8.95  16.04 0.578   0.108 
a Based on a model with a treatment by discrete time interaction differences are between AIBD and TAU  adjusting for sex, number of 
previous bipolar  episodes, baseline HAM-AD Anxiety subscale, the baseline score, and the interaction between the baseline score and 








Figure 1. Recruitment and retention 
Figure 2. Kaplan-Meier estimates of time to first depression or mania-type bipolar episode 
Figure 3. Kaplan-Meier estimates of time to first depression-type bipolar episode 
Figure 4. Kaplan-Meier estimates of time to first mania-type bipolar episode 
 
 
 
